Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
The purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as rATG or thymoglobulin) can have the same or fewer number of severe side effects in people with various blood cancers 30 days after they receive an allogeneic hematopoietic cell transplantation.
Hematologic Malignancies
DRUG: Busulfan 3.2 mg/kg/day|DRUG: Fludarabine|DRUG: Melphalan|DRUG: Antithymocyte globulin (ATG)|DRUG: Busulfan 0.8 mg/kg|PROCEDURE: Allogeneic hematopoietic cell transplantation (Allo-HCT)
the number of grade 4 toxicities, All grade 4 CTCAEv5.0 toxicities are included except for hematologic toxicities that are considered expected for patients receiving myeloablative conditioning., in the first 30 days post-HCT
The purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as rATG or thymoglobulin) can have the same or fewer number of severe side effects in people with various blood cancers 30 days after they receive an allogeneic hematopoietic cell transplantation.